INVESTORS & MEDIA
Corporate Governance
| Date | Name | Title | Filing | Type | Shares Traded | Price | Total Held |
|---|---|---|---|---|---|---|---|
| Apr 29, 2011 |
Director
Trans History: 312
|
Director | Form 4 | Conversion of derivative security | 20,000 | -- | 48,237 |
| Feb 11, 2011 |
SVP F&A, CFO, Treas & Asst Sec
Trans History: 645
|
SVP F&A, CFO, Treas & Asst Sec | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 20,000 | $19.43 | 97,734 |
| Feb 11, 2011 |
SVP F&A, CFO, Treas & Asst Sec
Trans History: 645
|
SVP F&A, CFO, Treas & Asst Sec | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 20,000 | -- | 30,911 |
| Jun 03, 2010 |
SVP F&A, CFO, Treas & Asst Sec
Trans History: 645
|
SVP F&A, CFO, Treas & Asst Sec | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 20,000 | $13.00 | 63,734 |
| Jun 03, 2010 |
SVP F&A, CFO, Treas & Asst Sec
Trans History: 645
|
SVP F&A, CFO, Treas & Asst Sec | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 20,000 | -- | 32,308 |
| Dec 18, 2006 |
SVP, Clinical Development
Trans History: 208
|
SVP, Clinical Development | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 20,000 | -- | 20,000 |
| Feb 07, 2006 |
Director
Trans History: 466
|
Director | Form 4 | Conversion of derivative security | 20,000 | -- | 35,258 |
| Feb 07, 2006 |
Director
Trans History: 466
|
Director | Form 4 | Conversion of derivative security | 20,000 | -- | 35,349 |
| Feb 11, 2005 |
Director
Trans History: 466
|
Director | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 20,000 | $6.00 | 25,258 |
| Feb 11, 2005 |
Director
Trans History: 466
|
Director | Form 4 | Open market or private sale of non-derivative or derivative security | 20,000 | $7.01 | 5,258 |
* Represents the number of non-derivative securities directly held. (I) Indicates that some (or all) of these shares are held indirectly.